BCL2 and acute myeloid leukemia: The selective BCL2 inhibitor ABT-199 (venetoclax), approved by the FDA for acute myeloid leukemia and chronic lymphocytic leukemia [86], demonstrated notable activity in a phase I clinical trial when combined with tamoxifen in ER+/HER2− ABC patients with BCL2 overexpression [87].